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ABSTRACT
DNAmethylationisthebest-studiedepigeneticmodi-
fication and describes the conversion of cytosine
to 5-methylcytosine. The importance of this phe-
nomenonisthataberrantpromoter hypermethylation
is a common occurrence in cancer and is frequently
associated with gene silencing. Various techniques
are currently available for the analysis of DNA
methylation. However, accurate and reproducible
quantification of DNA methylation remains challen-
ging. In this report, we describe Bio-COBRA (com-
bined bisulfite restriction analysis coupled with the
Agilent 2100 Bioanalyzer platform), as a novel
approach to quantitative DNA methylation analysis.
The combination of a well-established method,
COBRA, which interrogates DNA methylation via
the restriction enzyme analysis of PCR-amplified
bisulfite treated DNAs, with the Bioanalyzer platform
allows for the rapid and quantitative assessment of
DNA methylation patterns in large sample sets. The
sensitivityandreproducibilityofBio-COBRAmakeita
valuable tool for the analysis of DNA methylation in
clinical samples, which could aid in the development
ofdiagnosticandprognosticparameterswithrespect
to disease detection and management.
INTRODUCTION
Human cancers are characterized by profound alterations in
normal patterns of gene expression. In recent years, it has
become evident that epigenetic mechanisms are severely
affected in human neoplasias, which have been shown to
contribute to the initiation and progression of the disease
phenotype (1,2). Epigenetic modiﬁcations, such as DNA
methylation, are deﬁned as heritable modiﬁcations to the
DNA with the potential to alter gene expression while con-
serving the primary DNA sequence. DNA methylation occurs
primarily in the context of 50-CpG-30 dinucleotides (3–5). In
the human genome, almost 90% of all CpG dinucleotides are
located in repetitive sequences and are normally methylated.
Most of the remaining 10% stay methylation-free, and are
found in 0.5–4 kb sequence stretches termed CpG islands
(6,7). Interestingly, most CpG islands are located in close
proximity of genes or actually span gene promoters. The rel-
evance of this observation rests upon the fact that these
genes are consistently silenced when their associated CpG
island is methylated (8). Because of its potential to abrogate
gene activity, DNA methylation has been proposed as one of
the two hits in Knudson’s two hit hypothesis for oncogenic
transformation (1).
Studies have shown that aberrant DNA methylation can be
detected in body ﬂuids and secretions of patients years prior to
the clinical diagnosis of cancer, suggesting that aberrant DNA
methylation is manifested early in the process of malignant
transformation (2,9). Thus, much effort is being devoted to
further characterize aberrant DNA methylation patterns in
almost all tumor types in an attempt to uncover speciﬁc pat-
terns that might bear clinical diagnostic and prognostic value
(10–16). Given the fact that normal DNA methylation patterns
can vary among individuals, the speciﬁcity of one or several
aberrantDNAmethylationeventsmight restnotonlyonwhich
particular CpG dinucleotides are methylated, but also on
their methylation frequency (17). This possibility presents
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the search for aberrantly methylated loci useful for early
disease detection, assessment of disease risk or disease pro-
gnosis, may involve focusing on subtle changes in DNA
methylation. Thus, there is a need for a screening technique
that will allow for the rapid and reliable evaluation of DNA
methylation in large sample sets, while at the same time
providing quantitative information on the level of aberrant
DNA methylation and spatial information as to which CpG
dinucleotides are preferentially methylated in a genomic
region of interest.
Most techniques used to evaluate DNA methylation rely
on the bisulﬁte conversion of DNA (18). One such technique,
combined bisulﬁte restriction analysis (COBRA), involves
the PCR ampliﬁcation of bisulﬁte converted DNA foll-
owed by enzymatic digestion (19). COBRA is technically
simple, and depending on the region being investigated,
information on the methylation status of several CpG
sites can be extracted in a single reaction. Because of
these reasons, various DNA methylation laboratories use
COBRA as a screening method for large sample sets. The
main drawback of this assay is that quantitative information
cannot be obtained from the visual inspection of restriction
patterns.
The Agilent 2100 Bioanalyzer provides a robust platform
for the quantiﬁcation and high resolution of DNA fragments
via electrophoresis in microﬂuidics chips (20). This platform
has been utilized in various studies, primarily with the goal of
replacing or improving existing techniques, such as RFLP
(21,22), or attaining the visualization of PCR products that,
due to their low concentration, could not be detected in regular
agarose gels (23). However, to our knowledge, no study has
assessed the full potential of the Bioanalyzer platform as a
quantitative tool for the measurement of DNA methylation.
In this study, we propose the coupling of COBRA, followed
by quantiﬁcation of the restriction fragments on the Agilent
2100 Bioanalyzer platform for a rapid, accurate and cost-
efﬁcient quantiﬁcation of methylation patterns in any DNA
sample.
MATERIALS AND METHODS
Generation of DNA methylation standards and
bisulfite treatment
Genomic DNA was isolated from normal peripheral blood
lymphocytes (PBL) as described previously (24). Sheared
DNA (1 mg) was incubated at 37 C for 4 h with 100 U of
SssI (New England Biolabs, Beverly, MA) and 2 mlo f2 0m M
S-adenosyl methionine. The in vitro methylation reaction
was carried out twice, to ensure complete methylation. The
DNA was puriﬁed using Qiaquick columns (Qiagen, Valencia,
CA). The methylated and non-methylated DNAs were
concentration-adjusted to 20 ng/ml and mixed in ratios to
obtain samples with the following levels of DNA methylation:
1.6, 3.2, 6.4, 12.5, 25, 50, 75, 87.5, 93.6, 96.8 and 100%. Of
each DNA mixture 1 mg was bisulﬁte treated as described
previously (25) and diluted to a ﬁnal volume of 300 ml
with ddH2O. Of each mixture 10 ml was used for PCR
ampliﬁcation.
Culture and treatment of A549 cells with
5-aza-20deoxycytidine
A549 cell were incubated at 37 C, 5% CO2 in RPMI 1640
(Invitrogen, Carlsbad, CA), supplement with 10% heat-
inactivated fetal bovine serum (Invitrogen, Carlsbad, CA).
Cells were seeded at 10% conﬂuency, and treated with 5-
aza-20deoxycytidine (5-aza-dC) (Sigma-Aldrich, St Louis,
MO) at six different concentrations (0.05, 0.10, 0.50, 0.75,
1.00 and 2.00 mM) for 72 h. The demethylating agent was
supplied by diluting the appropriate amount of a 10 mM 5-aza-
dC stock in 10 ml of culture medium. The medium and
demethylating agent were changed daily. After the 72 h treat-
ment, the cells were washed with phosphate-buffered saline
(Invitrogen, Carlsbad, CA), incubated with 2 ml of 0.25%
trypsin for 5 min (Invitrogen, Carlsbad, CA) and collected
in 15 ml tubes.
DNA and RNA isolation from A549 cells
Total RNA was isolated using Trizol (Invitrogen, Carlsbad,
CA). The aqueous phase from each sample was mixed with
2 vol of RLT buffer (Qiagen, Valencia, CA), 1 vol of 100%
ethanol and ﬁltered through RNeasy columns (Qiagen, Valen-
cia, CA) following the manufacturer’s recommendations.
Genomic DNA was isolated from the Trizol phase remaining
after removal of the aqueous fraction containing total RNA,
following manufacturer’s recommendations. DNA pellets
were dissolved in 50 mlo fd d H 2O.
PCR amplification and restriction enzyme digestion
SALL3, C/EBPa and TWIST2 PCR primers to amplify bisul-
ﬁte treated DNA were designed using MethPrimer (26,27). In
order to minimize the preferential ampliﬁcation of either
methylated or unmethylated sequences, no CpG dinucleotides
wereincludedinthebisulﬁteprimersequences.Thespeciﬁcity
of the primers for bisulﬁte converted templates was tested by
their failure to PCR amplify sheared, non-bisulﬁte treated,
human genomic DNA. The sequences of the primers used
were as follows: SALL3, forward 50-GTTTGGGTTTGGTTT-
TTGTT-30, reverse 50-ACCCTTTACCAATCTCTTAACTT-
TC-30; C/EBPa, forward 50-TTGTTAGGTTTAAGGTTAT-
TG-30, reverse 50-TCAACTAAACCCAAATAAAA-30;
TWIST2, forward 50-AAGGGGGAGGTAAAATTGAAA-30,
reverse 50-CTAAACTAAATTACTAAATAATTATC-30.
PCR ampliﬁcations were performed as follows: 95 C for
10 min, (96 C for 30 s, annealing for 30 s, 72 C for 30 s)
for 35 cycles, with a ﬁnal step at 72 C for 10 min. The anneal-
ing temperatures and PCR product sizes were 59 C and 208 bp
for SALL3, 53 C and150 bp forC/EBPa and 52 Cand 141 bp
for TWIST2. PCRs were carried out in a 50 ml volume
containing 10· buffer (25), 6 ml of each primer (10 pmol),
1 ml (10 mM) dNTPs, 2 U of Platinum Taq DNA polymerase
(Invitrogen, Carlsbad, CA), 29.25 ml ddH2O and 10 mlo f
bisulﬁte treated DNA. PCR ampliﬁcations were performed
in a GeneAmp 9700 thermal cycler (Perkin-Elmer, Norwalk,
CT). PCR products were puriﬁed using Qiaquick columns,
eluted in 40 ml 10 mM Tris, pH 8.0, and concentrated to a
ﬁnal volume of 7 ml using a SpeedVac (Eppendorf, Hamburg,
Germany). Restriction digestions were performed using
10 U of BstUI (New England Biolabs, Beverly, MA) in a
total volume of 10 mla t6 0  C for 4 h. The digestion
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gel and visualized by ethidium bromide staining. Complete
digestion of the PCR product was assessed by the lack of
full-length fragments in the 100% in vitro methylated
samples.
Electrophoresis on the Agilent 2100 Bioanalyzer
platform
In order to determine whether the amount of input DNA
had an inﬂuence on DNA methylation measurements, a
sample of known methylation percentage was loaded (concen-
tration range of 10–65 ng/ml) in each of the wells of the
DNA 500 LabChip. Tabulation of the data obtained from
these measurements indicated that DNA concentration
within the tested range had no effect on the DNA methylation
values obtained for each of the samples. Furthermore, no
positional effect within the Chip was observed (Supplement-
ary Data).
For experimental samples, 20–40 ng of each of the digestion
products was loaded onto a DNA 500 LabChip and assayed
usingthe Bioanalyzer 2100. The chromatograms were visually
examined, raw data was exported as CSV-ﬁles using the
2100 expert software and subsequently plotted to obtain the
ﬂuorescence values for each of the fragments. The sensitivity
of the system was examined by determining the lowest
percentage of the standard methylation mix that yielded
restriction fragments with ﬂuorescence values above back-
ground. The background was deﬁned as the mean plus three
SDs of 10 measurements in front of the peak.
Data analysis and quantification of DNA methylation
The ﬂuorescence and migration time raw data for each
sample were plotted into Excel graphs. For quantiﬁcation,
the peak height generated by each DNA fragment was
utilized. Thus, for each sample, a table was created listing
the expected DNA size fragments and the ﬂuorescent signal
generatedby each of thosefragments.The methylationpercent
value for each sample was calculated using the following
formula: ﬂuorescence of methylated products/(ﬂuorescence
of methylated products + ﬂuorescence of unmethylated pro-
duct). The use of this calculation makes it possible to compare
methylation percentages across an entire sample set, because
the methylation value of each sample is normalized within
itself by computing the total ﬂuorescence generated by each
sample. The methylation percentages for each of 12 data
points of the in vitro methylated standard were plotted and
a model was generated for each of the three genes tested. The
in vitro generated methylation standard was tested at least
three times for each of the genes. The r
2 values for the models
were >0.98 in all cases.
Real-time quantitative PCR
Total RNA (1 mg) extracted from H1299 cells treated with 5-
aza-20-dC was incubated with 2 U of DNAseI (Invitrogen,
Carlsbad, CA) for 30 min at room temperature. The DNA-
free RNA was reverse transcribed using 100 U of SuperScript
II(Invitrogen,Carlsbad,CA)and1mgofoligodTperreaction.
Quantitative C/EBPa expression was measured using SYBR
Green I (BioRad, Hercules, CA) in an I-Cycler (BioRad,
Hercules, CA). Calcium/calmodulin-dependent protein
kinase kinase 2 (CAMKK2) was used as the internal control.
I-Cycler conditions were as follows: 10 min at 95 C; 35 cycles
with 30 s at 95 C, 30 s at 60 C (for CAMKK2) or 64 C (for C/
EBPa), 30 s at 72 C. At the end of the ampliﬁcation cycles, a
melting curve was generated, yielding a single peak of the
expected melting temperature for the desired products. For the
described assay the following primers were used: C/EBPa
forward 50-TGTATACCCCTGGTGGGAGA-30 and reverse
50-TCATAACTCCGGTCCCTCTG-30; CAMKK2 forward
50-CTCTTCCAGTGGGCAAAGAG-30 and reverse 50-
GTGTCAACAAGGGGCTCAAT-30. Prior to real-time
PCR, a regular PCR was performed on DNAseI incubated
but non-RT-treated samples in order to ensure that no DNA
contamination was present in the RNA extract, given the fact
that C/EBPa is an intron-less gene. The PCR products were
run on an 8% polyacrylamide gel. No product of the expected
C/EBPa size was detected in those reactions, indicating the
absence of contaminating genomic DNA in the DNAseI trea-
ted RNA extracts.
RESULTS
Measurement of a gradient of in vitro methylated DNA
The Agilent 2100 Bioanalyzer provides a platform for the
electrophoresis of nucleic acids on a disposable chip
(22,28). In this study, chemistry suitable for the resolution
of fragments from 25 to 500 bp was utilized. In order to
test our method, a methylation gradient was generated by
mixing in vitro methylated DNA with PBL DNA (Materials
and Methods). The samples were PCR ampliﬁed using three
pairs of COBRA primers for three different genes (SALL3,
C/EBPa and TWIST2) and digested with BstUI. Digestion
products were electrophoresed in an 8% polyacrylamide
gel and visualized by ethidium bromide staining. Complete
digestion of the PCR products was determined by the lack
of full-length PCR fragments (208 bp for SALL3 and 141 bp
for TWIST2) in the 100% methylated samples (Figure 1A
and B). Each digestion product (1 ml) was then loaded
into individual wells on a chip and electrophoresed in the
Bioanalyzer. Virtual gels were visually analyzed and the
ﬂuorescence data generated was tabulated and graphed
(Figure 1C and D).
Quantification of methylation percentages
The 2100 expert software provides quantiﬁcation for each
DNA fragment. However, quantiﬁcation by this software is
generated by calculating peak area measurements, which rely
heavily on the deﬁnition of the start and end points of a peak
(29). In order to eliminate the possibility of inaccurate quan-
tiﬁcation due to poor deﬁnition of peak areas, peak height was
utilizedasthe quantiﬁcationparameter. The peak heights of all
digested fragments was added and then divided by the peak
height of digested fragments plus the undigested fragment for
each sample, resulting in the observed methylation value. The
observed/expected methylation values were plotted for the
three genes (Figure 2). The equation derived from the
model was used to calculate DNA methylation percentages
in experimental samples.
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accuracy of Bio-COBRA
The sensitivity of Bio-COBRA was determined by testing the
1.6% sample of the methylation gradient. Because it is known
that PCR ampliﬁcation efﬁciency can vary signiﬁcantly
depending on the primer pair utilized and the target sequence,
three genes were selected so as to provide a variable input for
the assay. Fluorescent signals atleast2-foldabove background
could be generated from the restriction fragments of all three
genes (Supplementary Data).
Since ﬁnal DNA concentration after PCR ampliﬁcation
might vary among samples within a given set, the effect of
input DNA concentration on methylation measurements was
tested for SALL3 PCR products. Input DNA concentration
within the range of 10–65 ng/ml showed no inﬂuence on
methylation measurements. Also no positional effect within
the Chip was observed (Supplementary Data).
The accuracy of Bio-COBRA was assessed by comparing
TWIST2 methylation results obtained via this method with
data generated through Southern blotting of COBRA digests
probed with radioactively labeled primers [for a description of
the assay see (30)]. The data generated by both methods was
comparable, yielding similar overall methylation percentages
for the sample set (Figure 3A). To further validate these ana-
lyses, bisulﬁte DNA sequencing was performed in a subset of
the samples (30).
The reproducibility of Bio-COBRA was tested by compar-
ing the methylation percentages generated by the methylation
gradient in at least three different runs of the same restriction
digest for each of the three genes. When different runs of the
same gene were plotted and compared, almost identical
equations were derived from each one, all of them with r
2
values >0.98 (data not shown).
QuantificationofDNAmethylationinA549 cells treated
with 5-aza-20deoxycytidine
DNA methylation levels of SALL3 and C/EBPa were
examined in A549 cells before and after treatment with
0.05, 0.10, 0.50, 0.75, 1.00 and 2.00 mM of 5-aza-dC for 72 h.
Bio-COBRA results showed that DNA demethylation at these
loci occurred most efﬁciently when the cells were exposed to
low doses of 5-aza-dC (Figure 3B, C, E and F). In agreement
with previous reports, high doses of the demethylating agent
(1.00 and 2.00 mM) had a comparatively minor effect on DNA
demethylation in these loci (31). mRNA expression levels for
SALL3 and C/EBPa were also assessed in this cell line.
SALL3 data indicated that, at 0.10 mM of 5-aza-dC, mRNA
re-expression occurred if the level of DNA methylation
dropped below 69% at the restriction sites analyzed
(Figure 3G). This is an important observation, since it pro-
vided insight as to what the minimum effective dose of
5-aza-dC needed for mRNA re-expression for this speciﬁc
locus was. Overall, the data from both genes indicated that
exposure of the cell line to 5-aza-dC resulted in up-regulation
of SALL3 and C/EBPa at the mRNA level (Figure 3D and G).
However, it is important to note that the level of mRNA up-
regulation did not correlate directly with the level of DNA
methylation after 5-aza-dC treatment. This is an indica-
tion that the demethylating agent is affecting gene expres-
sion via a mechanism not limited to the removal of DNA
methylation (32).
Figure 1.DNAmethylationstandardsforSALL3(A)andTWIST2(B).Fragmentsizesareindicatedtotherightofthegel.Methylationpercentagesforeachlaneare
indicated at the top. The restriction map of the sequence is indicated at the bottom of the gel. BstUI sites are indicated with vertical lines on the restriction map.
(C) Exampleofa SALL3virtualgelgeneratedbytheBioanalyzersoftware.(D) Fluorescenceversustimedataplotforlanes8and9from(C).Fromrightto left,the
fluorescencepeakscorrespond tothe followingdigestionfragments:208,124,36 and26bp. The22 bpfragmentoverlapswiththefront marker.Asthemethylation
percentofthesampleincreases,thereisadecreaseinthefluorescenceofthe208bppeakandanincreaseinthefluorescenceofthedigestedpeaks(75%versus87.5%
plots). Plots likes the ones shown in this figure were used to calculate methylation percentages for all standards and samples tested.
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Epigenetic mechanisms play a major role in the initiation and
progression of human neoplasias. There is currently a large
body of evidence that indicates DNA methylation might be an
early event in tumor development, since aberrantly methylated
DNA molecules can be found in secretions and body ﬂuids of
individuals years in advance to the clinical diagnosis of cancer
(2,12,33). Thus, early detection of aberrant DNA methylation
patterns might provide a gateway for early disease detection
and the assessment of treatment strategies, as well as disease
prognosis. In order to achieve this goal, however, sensitive,
reliable and cost-effective assays for the quantiﬁcation of
DNA methylation are needed.
COBRA is commonly used for the screening of aberrant
DNA methylation in large sample sets. This is because
COBRA allows for the interrogation of CpG sites over relat-
ively large sequence stretches, and depending on the sequence
being analyzed, the use of several restriction enzymes can
increase the number of informative CpG sites examined within
thatsequence.COBRAisalsotechnically simpleandthe assay
is well established in most DNA methylation laboratories.
However, it is important to note that COBRA only provides
information on the DNA methylation status of those CpG sites
which are part of the restriction enzyme’s recognition
sequence. Thus, some sequences might not be suitable for
COBRA analysis due to their lack of restriction enzyme sites.
The main drawback of COBRA is that quantitative informa-
tion cannot be readily extracted from the assay. Attempts have
been made to quantify COBRA results by blotting and hybrid-
izing the restriction products with radiolabeled primers (30).
Although successful results were obtained from this approach,
the method is laborious and it involves the use of a radioactive
isotope. Attempts have also been made to quantify DNA
fragment intensities through the use of imaging softwares
on ethidium bromide stained gels. The problem of this
approach is its intrinsically narrow dynamic range, leading
to underestimation of strong signals. Furthermore, the ﬂuor-
escence background of gel images is often variable (from gel
to gel or from lane to lane within the same gel), affecting the
calculations and thus making it impossible to reliably compare
DNA methylationlevelsacross a sample set. Other techniques,
such as methylation-sensitive single nucleotide primer exten-
sion (34) and enzymatic regional methylation assay (35),
though sensitive, are time consuming and also require the
use of radioisotopes, making them unsuitable for the high-
throughput screening needs of a clinical setting. Bisulﬁte
DNA sequencing (18) is currently one of the most common
techniques utilized when quantitative information on DNA
methylation is desired. This technique allows for the assess-
ment of the methylation status of every CpG dinucleotide in a
given sequence, allowing for the high resolution of DNA
methylation patterns. However, there are several drawbacks
concerning this approach; mainly that it is laborious (cloning
of PCR fragments, bacterial transformation, plasmid isolation
and DNA sequencing) and, due to the cost of sequencing,
usually only 10 clones per sample are analyzed. The limited
number of clones examined per sample drastically reduces the
statistical power of bisulﬁte sequencing data. If, for example,
5 out of 10 clones are methylated at any given site, the 95%
conﬁdence interval for the true proportion of DNA methyla-
tion atthat siteisbetween18.4and81.6%.Also,ifa difference
in DNA methylation of 20% between two samples (from 50 to
70%), is to be statistically validated, 100 clones for each
sample would have to be sequenced and analyzed.
Direct sequencing of PCR products affords a high-
throughput platform; however, no quantitative information
can currently be extracted from the chromatograms. Thus
direct sequencing of PCR products with a mosaic methylation
pattern would result in the observation of methylated and
unmethylated cytosine at any given position in the sequence
without any information as to the relative amounts of each.
In this study, we combined a standard COBRA assay with
the quantiﬁcation capability afforded by the Agilent 2100
Bioanalyzer. The main strength of our approach is that it
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Figure 2. Plots of observed versus expected DNA methylation values
for SALL3, TWIST2 and C/EBPa methylation standards. (A) SALL3,
(B) TWIST2 and (C) C/EBPa results. Trend lines and r
2 values are displayed
for each plot. The non-linearity of the observed versus expected methylation
values is most likely due to a PCR amplification bias.
PAGE 5 OF 8 Nucleic Acids Research, 2006, Vol. 34, No. 3 e17Figure 3. AssessmentofDNAmethylationinclinicalCLLsamplesandahumanlungcancercelllinetreatedwith5-aza-20dC.(A)MethylationlevelsofTWIST2in
19 primary CLL samples generated by Bio-COBRA and Southern blot. The correlation coefficient between the two data sets was 0.98. (B and E) Restriction
digestions of SALL3 (B) and C/EBPa (E) in A549 cells treated with 5-aza-dC at six different concentrations for 72 h (concentrations are indicated at the top).
(C and F) Bio-COBRA quantification of the restriction digestions shown in (B) and (E). As expected, low doses of the demethylating agent showed a pronounced
effect in the DNA methylation status of the analyzed loci. (D and G) mRNA expression level of SALL3 (D) and C/EBPa (G). Three separate measurements were
performed for each sample. For C/EBPa, the expression level measured in the untreated cell line was normalized to 1. For SALL3, the expression level detected at
0.10 mM was normalized to 1, since the untreated cell line shows no expression under the experimental conditions utilized in this study.
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of DNA methylation percentages on a platform that enables
the comparison of these values across large sample sets. As
demonstrated, the data generated by this method is highly
reproducible and by making use of an in vitro methylated
DNA standard, experimental values can be converted to actual
methylation values in a single step. No DNA methylation
standard is needed, however, if the goal of a screen is only
a relative comparison of DNA methylation levels across a
sample set. Most importantly, no saturation of the system
was observed within the dynamic range tested in our study
(10–65 ng/ml). The tested dynamic range ensures that virtually
any PCR product can be digested without having to adjust the
DNA concentration of any sample (this range encompasses
PCRs performed in a 50 ml volume with a total DNA yield
ranging from 500 ng to 3.25 mg).
It should also be noted that the bisulﬁte DNA conversions
performed in this study used 1 mg of genomic DNA as sub-
strate. However, bisulﬁte conversion of DNA has been suc-
cessfully carried out using much smaller amounts of starting
material (36). Since the bisulﬁte converted DNA is later used
asPCR template,the sensitivityof the primers andthe intrinsic
properties of the target sequence are the factors that determine
as to how low an amount of DNA is needed as starting mater-
ial. Based on the presented results, Bio-COBRA affords an
alternative approach to other well-established methods, such
as pyrosequencing (37,38) and quantitative methylation spe-
ciﬁc PCR (39), for quantitative DNA methylation analysis in
epigenetic studies.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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